• Ascentage Pharma Group International shareholders held an annual general meeting on May 20, 2026.
• The audited consolidated financial statements and the directors’ and auditor’s reports for the year ended Dec. 31, 2025 were adopted.
• Ernst & Young was reappointed as auditor.
• A general mandate was granted to directors to issue shares up to 20% of the shares in issue; a separate mandate was granted to repurchase shares up to 10%, with an extension approved to increase the issuance mandate by the number of shares repurchased under that authority.
• Shareholders approved amendments to the memorandum and articles of association; proposed grants of RSUs under the 2022 RSU Scheme and Options under the Post-IPO Share Option Scheme were also approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-060305), on May 22, 2026, and is solely responsible for the information contained therein.